Dynavax Shareholders Investigate Proposed Sale to Sanofi

lunes, 29 de diciembre de 2025, 6:40 pm ET1 min de lectura
DVAX--
SNY--

Kahn Swick & Foti is investigating the proposed sale of Dynavax Technologies Corporation to Sanofi, questioning the adequacy of the price and process. Shareholders will receive $221.50 in cash for each share, with KSF seeking to determine if the consideration undervalues the company. Those interested can contact Lewis S. Kahn at 855-768-1857 or visit www.ksfcounsel.com for more information.

Dynavax Shareholders Investigate Proposed Sale to Sanofi

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios